Research programme: CAR-T anticancer therapeutics - Atossa Genetics

Drug Profile

Research programme: CAR-T anticancer therapeutics - Atossa Genetics

Alternative Names: TRAP CAR-T - Atossa Genetics

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atossa Genetics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 02 Oct 2017 Research programme: CAR-T anticancer therapeutics - Atossa Genetics is available for licensing as of 02 Oct 2017. http://www.atossagenetics.com/
  • 02 Oct 2017 Early research in Breast cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top